Mesirow Financial Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mesirow Financial Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Sell	628 -50	-7%	-$22.2K	﹤0.01%	439
2026 Q1	$303K	Buy	678 +185	+38%	+$86.3K	﹤0.01%	427
2025 Q4	$224K	Sell	493 -186	-27%	-$80.2K	﹤0.01%	449
2025 Q3	$266K	Buy	679 +55	+9%	+$23K	﹤0.01%	478
2025 Q2	$278K	Sell	624 -5	-0.8%	-$2.3K	0.01%	452
2025 Q1	$305K	Buy	629 +61	+11%	+$28.4K	0.01%	452
2024 Q4	$229K	Sell	568 -412	-42%	-$191K	﹤0.01%	524
2024 Q3	$456K	Hold	980	–	–	0.01%	375
2024 Q2	$459K	Buy	+980	New	+$425K	0.01%	343

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mesirow Financial Investment Management's VRTX Position: Q2 2026 in Review

Mesirow Financial Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 7.4% in Q2 2026, selling an estimated $22.2K and leaving 628 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #439.

Mesirow Financial Investment Management first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $459K in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Mesirow Financial Investment Management held 628 shares of Vertex Pharmaceuticals worth $312K as of Q2 2026.
Mesirow Financial Investment Management sold 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
Vertex Pharmaceuticals made up ﹤0.01% of Mesirow Financial Investment Management's portfolio in Q2 2026, its #439 holding.
Mesirow Financial Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Mesirow Financial Investment Management's Vertex Pharmaceuticals position peaked at $459K in Q2 2024.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.